Results 71 to 80 of about 16,189 (104)

The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis [PDF]

Multiple sclerosis is the most common autoimmune disease affecting the central nervous system (CNS) worldwide. Multiple sclerosis involves inflammatory demyelination of nerve fibers in the CNS, often presenting with recurrent episodes of focal sensory or
Le, Viet, Anderson, Lillian, Mosieri, Chizoba N, Boggio, Nicole A, Ahmadzadeh, Shahab, Paladini, Antonella, Kaye, Adam M, Lacey, John, Varrassi, Giustino, Robinson, Christopher L, Askins, Dorothy H, Kaye, Alan D, Fazal, Ahmed, Shekoohi, Sahar   +13 more
core   +1 more source

Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate. [PDF]

Cureus, 2023
Gül S, Ahmed AF, McGraw C.
europepmc   +1 more source

Exploring the dual role of fumarate as an intracellular and extracellular hypoxia-induced signalling molecule [PDF]

Myocardial ischemia is characterised by a restriction in blood flow to the heart, which limits nutrient and oxygen supply and removal of waste products. In healthy hearts, ischemia triggers a cardiac metabolic shift from oxidative metabolism to anaerobic
Castro Guarda, Marcos Felipe
core   +1 more source

Biochemical, structural and functional characterization of diheme-containing quinol:fumarate reductases : the role of heme propionates and the enzymes from pathogenic e-proteobacteria [PDF]

, 2005
The quinol:fumarate reductase (QFR) is the terminal reductase of anaerobic fumarate respiration, the most commonly occurring type of anaerobic respiration.
Mileni, Mauro
core  

Diroximel fumarate for multiple sclerosis. [PDF]

Aust Prescr, 2022
europepmc   +1 more source

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence. [PDF]

Neurol Ther, 2021
Liseno J, Lager B, Miller C, Shankar SL, Mendoza JP, Lewin JB.   +5 more
europepmc   +1 more source

Effect of Diroximel Fumarate on gut dysbiosis and neuroinflammation

Neurotherapeutics
Sudhir Kumar Yadav, Ph.D., Naoko Ito, Shradha Suresh, Yaritza Rosario, Tamar Kalina, Sai L. Shankar, Ph.D., Kouichi Ito, Ph.D., Suhayl Dhib-Jalbut, M.D.   +7 more
doaj   +1 more source

Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes. [PDF]

Adv Ther
Bandari D, Conway D, Dong L, Hong N, Li M, Littlewood A, Roy M, Ulin S, Zou C, Amerian-Williams B, Belviso N, Lewin JB, Mendoza JP, Avila M.   +13 more
europepmc   +1 more source

Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy. [PDF]

Neurodegener Dis Manag
Roman C, Garabedian M, Schobel VR, Schneider B, Luce E, Mendoza JP, Lewin JB, Shankar SL.   +7 more
europepmc   +1 more source

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations

, 2016
Luca Prosperini, Simona Pontecorvo Department of Neurology and Psychiatry, Sapienza University, Rome, Italy Abstract: Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying ...
Prosperini L, Pontecorvo S
core